JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia

Leuk Res. 2009 Nov;33(11):e212-3. doi: 10.1016/j.leukres.2009.06.011. Epub 2009 Jul 9.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Janus Kinase 2 / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Mutation*
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • JAK2 protein, human
  • Janus Kinase 2